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ABSTRACT  
The primary objective of this study was to assess whether the topical administration of two 
neuroprotective drugs (brimonidine and somatostatin) could prevent or arrest retinal 
neurodysfunction in diabetic patients with type 2 diabetes. For this purpose, adults aged between 
45 and 75 years with a diabetes duration ≥ 5 years, and an ETDRS level ≤35 were randomly 
assigned to one of 3 arms: placebo, somatostatin and brimonidine.  The primary outcome was the 
change in Implicit Time (IT) assessed by mfERG between baseline and at the end of follow-up (96 
weeks). A total of 449 eligible patients were allocated to brimonidine (n=152), somatostatin 
(n=145) and placebo (n=152). When the primary end-point was evaluated in the whole population 
we did not find any neuroprotective effect of brimonidine or somatostatin. However, in the subset 
of patients with pre-existing retinal neurodysfunction (34.7%), IT worsened in the placebo group 
(p<0.001), but remained unchanged in the brimonidine and somatostatin groups. In conclusion, the 
topical administration of the selected neuroprotective agents appears useful in preventing the 
worsening of pre-existing retinal neurodysfunction. This finding points to screening retinal 
neurodysfunction as a critical issue to identify a subset of patients in whom neuroprotective 
treatment might be of benefit. 
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3INTRODUCTION 
Diabetic retinopathy (DR) is classically considered a microvascular disease. However, growing 
evidence suggests that abnormalities in retinal function can be detected in patients without any 
evidence of microvascular abnormalities (1,2). In addition, it has been suggested that diabetes-
induced retinal dysfunction might contribute to the development of microvascular abnormalities 
(2). Therefore, it is reasonable to hypothesize that therapeutic strategies aimed at neuroprotection 
may also be effective in preventing the development and progression of microvascular disease. In 
fact, there is experimental evidence to support this concept (3,4). 
In the early stages of diabetes a high proportion of patients present deficiencies such as decreased 
hue discrimination and contrast sensitivity, delayed dark adaptation, abnormal visual fields, and 
impairment of vision related quality of life (5-7). Therefore, neuroprotection itself can be 
considered a therapeutic target, independently of its potential to prevent the development or 
progression of microangiopathy (8). 
A number of therapeutic strategies based on the main pathogenic mechanisms involved in 
neurodegeneration have been proposed (9).  Systemic administration of drugs blocking these 
pathways is very unlikely to reach the retina at pharmacological concentrations and, in addition, 
could have serious adverse effects. On the other hand, if the early stages of DR are the therapeutic 
target, aggressive treatments such as intravitreal injections would be unacceptable. Topical 
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4treatment with neuroprotective agents in the form of eye drops has been neglected as a possible 
option because of a general assumption that the posterior chamber of the eye cannot be reached by 
this route. However, there is emerging evidence that several peptides administered by eye drops 
are able to reach the retina in pharmacological concentrations, at least in animal models (3, 10-13). 
Topical administration has the advantage of concentrating drug action to the eye while potentially 
minimizing systemic effects.
On this basis we conducted the first clinical trial aimed at evaluating the effects of topically 
administered neuroprotective agents in diabetic patients with no or mild DR. The selected drugs 
were brimonidine and somatostatin, which have already shown their neuroprotective action in 
preclinical studies (11, 14). The primary objective was to assess whether these drugs administered 
topically were able to prevent or arrest neurodegeneration as assessed by mfERG. The main 
secondary objectives were to evaluate their safety, and to examine their potential impact on the 
development or progression of DR in terms of microvascular disease.  
METHODS
Study design and participants
In this randomized, placebo-controlled, phase II-III trial of parallel groups a total of 450 patients 
with type 2 diabetes were enrolled at 11 European centers belonging to the EUROCONDOR 
consortium. The trial (NCT01726075) was funded by the European Commission 7th Framework 
Programme. The protocol (Supplementary Material) was approved by the local research ethics 
committee at each site. All participants provided their written informed consent.
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5Eligibility criteria were age between 45 and 75 years, a diagnosis of type 2 diabetes with a known 
duration ≥ 5 years, and an Early Treatment for Diabetic Retinopathy Study (ETDRS) ≤ 35. 
Exclusion criteria were previously detailed (15). 
Randomization and masking
Eligible patients (n= 449) (Supplementary Fig. S1) were randomly allocated in a 1:1:1 ratio to 
placebo, somatostatin 0.1%, and brimonidine tartrate 0.2% (1 drop BID in each eye in all cases). 
Randomization was based on a minimization algorithm that balanced the three groups, stratified 
by ETDRS level (<20 vs. 20-35). 
Procedures
Each patient underwent a comprehensive ophthalmic examination as previously reported (15). 
Only one eye from each patient was included in the study. If both eyes met the inclusion criteria, 
one of them was chosen randomly. 
Multifocal ERG Recording and Analysis 
The mfERGs were recorded in the study eye using the RETI-port/scan 21 (Roland Consult, Berlin, 
Germany) visual electrophysiology system. Detailed information regarding the methodology used 
has been previously reported (15).
OCT Imaging and Analysis
SD-OCT images were acquired according to standardized protocols by CIRRUS HD-OCT (Zeiss 
Meditec), or by Topcon 3D-OCT 2000 (Topcon Corporation), henceforth designated as Topcon, 
depending on the equipment available at each site. A total of 284 patients underwent CIRRUS HD-
OCT imaging, while 165 patients underwent Topcon 3D-OCT 2000 imaging. Further details on 
the methodology have been previously reported (15). 
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6Follow-up, outcome measurements and adverse events and compliance
Patients were followed and treated during a 96-week period. Study visits were scheduled as detailed 
in the protocol (Suppl Material) every 24 weeks. 
The presence of neurodysfunction was defined as an eye with ≥6 altered hexagons for Implicit 
Time (IT) (16). An altered hexagon was defined as a hexagon with a z-score 2 or higher for IT in 
comparison with a normative database that was previously created (17). 
The primary outcome was the change in the IT assessed by mfERG (between baseline and the end 
of follow-up). 
Secondary outcomes were: other neurodegenerative variables (thickness of the retinal nerve fibre 
layer [RNFL] and ganglion cell layer [GCL] assessed by SD-OCT), microvascular variables 
(microaneurysm turnover assessed by colour fundus photography, central retinal thickness assessed 
by SD-OCT, DR severity assessed by the ETDRS scale, best corrected visual acuity (BCVA) 
assessed by the ETDRS scale and visual field defects assessed by the Visual Fields Test.
Safety evaluation included assessment of: intra-ocular pressure (IOP), BCVA, conjunctival 
redness, biomicroscopy, visual fields, blood pressure, heart rate and laboratory safety variables (i.e. 
blood count and blood biochemistry). In addition, reported adverse events such as overall drop 
discomfort were recorded.
 A compliance of 60% was considered appropriate for this study. If compliance was below 60% or 
patients interrupted the study medication for more than 1 month, they were not evaluable for 
efficacy
Sample size calculation
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7Assuming that, at the end of the study, the placebo group would present 50% of abnormal mfERG 
IT versus 30% in the patients receiving the active drugs, the number of patients required in each 
group to demonstrate neuroprotection would be 93. However, as the progression of microvascular 
changes was also going to be analyzed, the progression rate for patients with very early ETDRS 
stages at study entry needed to be taken into account. Therefore, assuming that 30% of these 
patients would present some degree of worsening during the follow-up and that active therapy 
would reduce this figure to 15%, the number of patients required in each arm was 120. These 
estimates were performed to assess the efficacy of neuroprotective drugs (somatostatin or 
brimonidine) vs. placebo with a 2-side risk level of 0.05 and a statistical power of 80%. Taking 
into account a dropout rate of 20%, the final number of patients to be included in each arm would 
be 150.
Statistical analyses
For primary analyses (efficacy), we did the analyses per protocol (restricted to participants who 
completed the study) and by intention-to-treat. Pre-specified analyses for both the prevention and 
progression of neurodysfunction were performed. No imputations were done for missing data. The 
safety analysis population included the subjects who received at least one dose of study treatment. 
Statistical analysis was performed by TechnoSTAT (www.technostat.co.il) in close collaboration 
with the statistical team from AIBILI and VHIR. We used the two-tailed paired, or independent 
samples Student’s t-test, and ANOVA for continuous variables. Mixed-effect linear regression 
models adjusted by HbA1c were performed to evaluate IT progression during follow-up. To 
examine the association between categorical variables the Chi-Square was used.  Data are 
expressed as mean (± standard deviation) for continuous data, and as percentages for categorical 
data. All analyses were done with SAS® Version 9.4 under Windows® 2008 Terminal. 
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8RESULTS
Baseline characteristics and drop-outs
Between February 5, 2013 and 6 November, 2013, eligible patients (n=449) with type 2 diabetes were 
randomized. The characteristics of the treatment groups at randomization were well balanced in 
terms of age, HbA1c and cardiovascular risk factors as previously reported (15). 
According to the pre-defined criteria of this study, we found only 156 (34.7%) patients with 
mfERG abnormalities at baseline (patients with neurodysfunction). 
During the 2 years of follow-up a 24% (n=109) drop-out rate was observed, occurring mainly in 
the first year (Supplementary Fig. S2). The characteristics of patients included in the analysis of 
efficacy per-protocol according to treatment are shown in Table 1. 
Safety
Detailed information of serious adverse events (SAEs) is shown in supplemental material (Tables 
S1 and S2). Only 1 SAE (ocular hyperaemia) was considered related to the investigational drugs 
(brimonidine). The most frequent ocular adverse events are detailed in Supplementary Table S3. 
Brimonidine had more frequent adjudicated ocular adverse events. 
Effectiveness
We did not find any significant effect of brimonidine or somatostatin in comparison with placebo 
on the number of abnormal hexagons during follow-up in the whole population when the analysis 
was performed per-protocol (Table 2) or by intention-to-treat (p=0.75 and p=0.24, respectively). 
Pre-specified subanalyses were performed separately to examine the effects of the neuroprotective 
drugs in preventing neurodysfunction or arresting its progression. When patients without 
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9neurodysfunction at baseline were analysed, we did not find significant differences in the incidence 
of neurodysfunction at the end of the study. In contrast, both somatostatin and brimonidine were 
able to arrest the progression of pre-existing neurodysfunction. Therefore, those patients in whom 
some degree of neurodegeneration was already present (≥ 6 abnormal hexagons at the baseline), 
somatostatin and brimonidine were effective in preventing the increase of the mean IT that was 
observed in the placebo group (Figure 1A). However, when patients were analyzed per intention-
to-treat a clear tendency to increasing the IT in the placebo group was also observed but did not 
reach statistical significance (p=0.06) (Figure 1B). 
It is worth mentioning that there were no differences between the groups regarding the mean 
HbA1c during the trial. Therefore, our findings are not influenced by differences in the glycaemic 
control (Supplementary Table S4 and Table S5). 
Regarding the main pre-specified secondary objectives, we did not find any effect of brimonidine 
or somatostatin in preventing or arresting microvascular disease. 
Analyses of SD-OCT data revealed no difference in retinal thickness between the placebo, 
brimonidine or somatostatin arms at study entry or during follow-up (Table 3).
DISCUSSION
The concept of DR as microvascular disease has evolved into that of a more complex diabetic 
complication in which neurodegeneration plays a significant role (8). In fact, the American 
Diabetes Association has recently defined DR as a highly specific neurovascular complication (18). 
This is the first clinical trial using neuroprotective drugs for treating DR. We have found that eye 
drops containing neuroprotective agents (brimonidine or somatostatin) did not exert any apparent 
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effect in terms of primary prevention of neurodysfunction or in modulating the appearance and 
progression of microvascular disease, at least over 2 years of follow-up and using the methodology 
previously described. In the subgroup of patients with pre-existing retinal dysfunction, the agents 
tested were able to arrest the progression of IT only in patients who completed the study without 
any major protocol violations (per-protocol). Overall, our results suggest that topical administration 
of somatostatin or brimonidine failed in achieving the primary end point of this clinical trial. 
However, the subset of patients with neurodysfunction could be envisaged as a promising target 
population in future clinical trials designed to elucidate this issue. The lack of effectiveness in 
preventing neurodysfunction could be attributed to the short follow-up (2 years) and to the excellent 
metabolic control of the patients included in the study. 
The mechanisms by which brimonidine and somatostatin arrest the progression of 
neurodysfunction remain to be fully elucidated. Brimonidine has been shown to effectively 
promote the survival and function of retinal ganglion cells in a variety of animal models unrelated 
to diabetes (14). This is the first study showing that topical administration of brimonidine arrests 
the progression of retinal neurodysfunction in patients with type 2 diabetes. 
Somatostatin is abundantly produced by the human retina, the main source being the retinal 
pigment epithelium (19). Somatostatin exerts relevant functions in the retina (20). In the diabetic 
retina, a significant downregulation of somatostatin production has been reported (21-23). 
Therefore, a replacement treatment by the topical route can be envisaged as a reasonable approach 
for treating DR. The main reasons by which systemic administration of somatostatin analogues 
failed in arrest progression of DR have been recently reviewed (20), but one of the most important 
is their inability to cross the blood-retinal barrier. 
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Our results point to screening for retinal neurodysfunction as a critical issue to identify those 
patients in whom neuroprotective treatment might be of benefit. In this regard, mfERG is probably 
not a good option because it is a cumbersome and time-consuming method and, therefore, should 
be reserved for clinical trials. In addition, mfERG reflects only macular cone photoreceptor 
function and does not assess broader retinal integrity. Apart from mfERG other methods addressed 
to measure retinal function have been proposed (9). Among these methods, fundus driven 
microperimetry is a very sensitive, reliable and rapid method and, consequently, can be a useful 
tool to screen for neurodysfunction in clinical practice (24, 25).
Our study has several limitations. First, we found a lower prevalence of neurodysfunction than 
expected. Second, a low progression rate of microvascular disease was found. The inclusion by 
design of 43% of patients without any microvascular abnormalities at study entry, the short follow-
up (2 years) and the excellent HbA1c and blood pressure levels throughout were the main factors 
accounting for this low rate of DR progression. Third, the drop-out rate was higher than anticipated 
(24% vs. 20%), but the number of patients who completed the study was higher than required to 
achieve the primary end point. Finally, there was no way to determine quantitatively whether or 
not somatostatin and bimonidine reached the human neurosensory retinas in meaningful 
concentrations.
In conclusion, we did not find any significant effect of topical administration of brimonidine or 
somatostatin in preventing or arresting both neurodysfunction and microvascular disease in the 
whole population included in this study. However, these neuroprotective agents could play a role 
in reducing the progression of pre-existing neurodysfunction. Further studies using new 
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technologies and with longer follow-up addressed to confirm the neuroprotective effects in this 
subset of type 2 diabetic population, and whether they result in reduction of microvascular disease 
are needed.  
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Table 1. Baseline characteristics of patients with type 2 diabetes included in the analysis per- 
protocol.
Placebo Brimonidine Somatostatin
N=123 N=97 N=120
Age (years) 62.4±7.1 63.7±6.0 62.6±6.6
Gender (% males) 66.1 66.0 65.0
BMI (Kg/m2) 30.8±5.6 30.8±5.3 31.1±5.4
Diabetes duration (years) 11.6±5.8 11.1±5.5 11.4±5.5
Diabetes treatment (%)
Diet 4.8 2.1 4.2
Oral agents 65.3 76.3 73.3
Oral agents + Insulin 24.2 21.6 20.8
Insulin 5.6 0.0 1.7
HbA1C (%) 7.21±0.97 7.22±1.09 7.11±0.92
Hypertension (%) 71.0 73.2 71.7
Dyslipidemia (%) 69.4 67.0 67.5
Micro/macroalbuminuria (%) 19.3 22.7 19.1
Cardiovascular disease (%) 19.4 14.4 21.7
ETDRS <20/20-35(%) 42.7/57.3 38.1/61.9 43.3/56.7
BCVA letter score 85.9±5.2 86.1±5.2 85.7±4.6
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Table 2.  Effect of the investigational drugs on the number of abnormal hexagons assessed by 
mfERG.
Patients in whom abnormal hexagons did not 
increase compared to baseline
Patients in whom abnormal hexagons 
increased compared to baseline
N (%) N (%)
Placebo (n=123) 69 (56.1) 54 (43.9)
BRIM (n=97) 48 (49.5) 49 (50.5)
SST (n=120) 55 (45.8) 65 (54.2)
BRIM: brimonidine; SST: somatostatin. BRIM vs. placebo: p=0.29; SST vs. placebo: p=0.11
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Table 3. Changes in retinal thickness (RT) measured by SD-OCT. Data are mean ± standard 
deviation. 
Baseline
(µm)
24 months
(µm)
p
Placebo 255.14±25.93 253.63±25.16 0.06
BRIM 255.94±27.03 255.30±29.13 0.64
SST 256.20±28.23 257.14±29.73 0.31
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FIGURE LEGEND
Figure 1. Progression of IT (ms) during follow-up in patients with pre-existing neurodysfunction: 
A) Analysis per-protocol and B) Analysis by intention-to-treat. Black: placebo group; Red: 
brimonidine group; Blue: somatostatin group. Difference (change in IT) from baseline to month 24 
is expressed as mean (standard deviation). 
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Difference 95% Confidence Interval p-value
Placebo (n= 39) 0.539 (0.264) 0.021 ; 1.057 0.04
BRIM (n= 39) 0.006 (0.242) -0.468 ; 0.481 0.97
SST (n= 41) 0.108 (0.258) -0.398 ; 0.614 0.67
SD of Random effect =1.46
A)
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Intention-to-treat
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Difference 95% Confidence Interval p-value
Placebo (n= 49) 0.479 (0.259) -0.028;0.987 0.06
BRIM (n= 60) 0.041 (0.236) -.0422;050 0.86
SST (n= 47) 0.078 (0.254) -.421;058 0.76
SD of Random effect =1.49
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SUPPLEMENTAL MATERIAL
Clinical Protocol
Link to the protocol published in the clinical trials register:
https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-001200-38/DE
Table S1. Serious adverse events by body system, preferred term and treatment group. 
Brimonidine vs. Placebo Group
Treatment Group
Body System / Preferred Term
Brimonidine Placebo Any
Any Any
26; 21 (14%)
34; 23 
(15%)
60; 44 
(14%)
Any 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)Blood and lymphatic system disorders
Anaemia 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)
Any
5; 5 (3%) 7; 5 (3%)
12; 10 
(3%)
Angina unstable 0; 0 (0%) 2; 2 (1%) 2; 2 (1%)
Atrial fibrillation 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)
Atrial flutter 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)
Cardiac arrest 1; 1 (1%) 0; 0 (0%) 1; 1 (0%)
Cardiac failure 1; 1 (1%) 1; 1 (1%) 2; 2 (1%)
Coronary artery disease 2; 2 (1%) 1; 1 (1%) 3; 3 (1%)
Cardiac disorders
Myocardial infarction 1; 1 (1%) 1; 1 (1%) 2; 2 (1%)
Any 2; 2 (1%) 0; 0 (0%) 2; 2 (1%)
Glaucoma 1; 1 (1%) 0; 0 (0%) 1; 1 (0%)
Eye disorders
Ocular hyperaemia 1; 1 (1%) 0; 0 (0%) 1; 1 (0%)
Any 2; 2 (1%) 1; 1 (1%) 3; 3 (1%)
Colitis ischaemic 1; 1 (1%) 0; 0 (0%) 1; 1 (0%)
Enterocolitis 1; 1 (1%) 0; 0 (0%) 1; 1 (0%)
Gastrointestinal disorders
Lower gastrointestinal haemorrhage 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)
Any 1; 1 (1%) 0; 0 (0%) 1; 1 (0%)General disorders and administration site conditions
Condition aggravated 1; 1 (1%) 0; 0 (0%) 1; 1 (0%)
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Treatment Group
Body System / Preferred Term
Brimonidine Placebo Any
Any 1; 1 (1%) 0; 0 (0%) 1; 1 (0%)Hepatobiliary disorders
Jaundice cholestatic 1; 1 (1%) 0; 0 (0%) 1; 1 (0%)
Any 1; 1 (1%) 2; 2 (1%) 3; 3 (1%)
Gastroenteritis norovirus 1; 1 (1%) 0; 0 (0%) 1; 1 (0%)
Influenza 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)
Infections and infestations
Urinary tract infection 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)
Any 1; 1 (1%) 0; 0 (0%) 1; 1 (0%)Injury, poisoning and procedural complications
Tibia fracture 1; 1 (1%) 0; 0 (0%) 1; 1 (0%)
Any 1; 1 (1%) 0; 0 (0%) 1; 1 (0%)Metabolism and nutrition disorders
Dehydration 1; 1 (1%) 0; 0 (0%) 1; 1 (0%)
Any 1; 1 (1%) 1; 1 (1%) 2; 2 (1%)
Bursitis 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)
Musculoskeletal and connective tissue disorders
Osteoarthritis 1; 1 (1%) 0; 0 (0%) 1; 1 (0%)
Any
5; 5 (3%) 9; 8 (5%)
14; 13 
(4%)
Breast cancer 2; 2 (1%) 1; 1 (1%) 3; 3 (1%)
Chronic myeloid leukaemia 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)
Gastric cancer 1; 1 (1%) 0; 0 (0%) 1; 1 (0%)
Hepatic cancer 1; 1 (1%) 0; 0 (0%) 1; 1 (0%)
Malignant melanoma 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)
Malignant melanoma stage i 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)
Metastases to bone 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)
Rectal adenocarcinoma 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)
Rectal cancer 1; 1 (1%) 0; 0 (0%) 1; 1 (0%)
Renal cell carcinoma 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)
Neoplasms benign, malignant and unspecified (incl cysts 
and polyps)
Tongue neoplasm malignant stage 
unspecified 0; 0 (0%) 2; 2 (1%) 2; 2 (1%)
Any 1; 1 (1%) 5; 4 (3%) 6; 5 (2%)
Basilar migraine 1; 1 (1%) 0; 0 (0%) 1; 1 (0%)
Coma 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)
Ischaemic stroke 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)
Radicular pain 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)
Nervous system disorders
Radiculitis 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)
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Treatment Group
Body System / Preferred Term
Brimonidine Placebo Any
Transient ischaemic attack 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)
Any 1; 1 (1%) 1; 1 (1%) 2; 2 (1%)
Acute kidney injury 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)
Renal and urinary disorders
Renal failure 1; 1 (1%) 0; 0 (0%) 1; 1 (0%)
Any 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)Reproductive system and breast disorders
Benign prostatic hyperplasia 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)
Any 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)Respiratory, thoracic and mediastinal disorders
Obliterative bronchiolitis 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)
Any 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)Skin and subcutaneous tissue disorders
Skin ulcer 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)
Any 3; 3 (2%) 3; 3 (2%) 6; 6 (2%)
Breast operation 1; 1 (1%) 0; 0 (0%) 1; 1 (0%)
Hip arthroplasty 1; 1 (1%) 0; 0 (0%) 1; 1 (0%)
Skin neoplasm excision 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)
Surgery 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)
Transurethral prostatectomy 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)
Surgical and medical procedures
Umbilical hernia repair 1; 1 (1%) 0; 0 (0%) 1; 1 (0%)
Any 1; 1 (1%) 1; 1 (1%) 2; 2 (1%)
Aortic aneurysm 1; 1 (1%) 0; 0 (0%) 1; 1 (0%)
Vascular disorders
Peripheral artery stenosis 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)
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Table S2. Serious adverse events by body system, preferred term and treatment group. 
Somatostatin vs. Placebo Group
Treatment Group
Body System / Preferred Term
Somatostatin Placebo Any
Any Any
19; 12 (8%)
34; 23 
(15%)
53; 35 
(12%)
Any 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)Blood and lymphatic system disorders
Anaemia 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)
Any 5; 4 (3%) 7; 5 (3%) 12; 9 (3%)
Angina pectoris 1; 1 (1%) 0; 0 (0%) 1; 1 (0%)
Angina unstable 0; 0 (0%) 2; 2 (1%) 2; 2 (1%)
Atrial fibrillation 1; 1 (1%) 1; 1 (1%) 2; 2 (1%)
Atrial flutter 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)
Atrioventricular block complete 1; 1 (1%) 0; 0 (0%) 1; 1 (0%)
Cardiac failure 2; 2 (1%) 1; 1 (1%) 3; 3 (1%)
Coronary artery disease 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)
Cardiac disorders
Myocardial infarction 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)
Any 1; 1 (1%) 0; 0 (0%) 1; 1 (0%)Eye disorders
Visual impairment 1; 1 (1%) 0; 0 (0%) 1; 1 (0%)
Any 1; 1 (1%) 1; 1 (1%) 2; 2 (1%)
Duodenal ulcer haemorrhage 1; 1 (1%) 0; 0 (0%) 1; 1 (0%)
Gastrointestinal disorders
Lower gastrointestinal haemorrhage 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)
Any 1; 1 (1%) 0; 0 (0%) 1; 1 (0%)General disorders and administration site conditions
Chest pain 1; 1 (1%) 0; 0 (0%) 1; 1 (0%)
Any 1; 1 (1%) 0; 0 (0%) 1; 1 (0%)Hepatobiliary disorders
Cholelithiasis 1; 1 (1%) 0; 0 (0%) 1; 1 (0%)
Any 3; 3 (2%) 2; 2 (1%) 5; 5 (2%)
Influenza 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)
Lower respiratory tract infection 1; 1 (1%) 0; 0 (0%) 1; 1 (0%)
Pneumonia 1; 1 (1%) 0; 0 (0%) 1; 1 (0%)
Respiratory tract infection 1; 1 (1%) 0; 0 (0%) 1; 1 (0%)
Infections and infestations
Urinary tract infection 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)
Injury, poisoning and procedural complications Any 1; 1 (1%) 0; 0 (0%) 1; 1 (0%)
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Treatment Group
Body System / Preferred Term
Somatostatin Placebo Any
Hip fracture 1; 1 (1%) 0; 0 (0%) 1; 1 (0%)
Any 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)Musculoskeletal and connective tissue disorders
Bursitis 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)
Any 0; 0 (0%) 9; 8 (5%) 9; 8 (3%)
Breast cancer 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)
Chronic myeloid leukaemia 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)
Malignant melanoma 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)
Malignant melanoma stage i 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)
Metastases to bone 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)
Rectal adenocarcinoma 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)
Renal cell carcinoma 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)
Neoplasms benign, malignant and unspecified (incl cysts 
and polyps)
Tongue neoplasm malignant stage 
unspecified 0; 0 (0%) 2; 2 (1%) 2; 2 (1%)
Any 0; 0 (0%) 5; 4 (3%) 5; 4 (1%)
Coma 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)
Ischaemic stroke 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)
Radicular pain 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)
Radiculitis 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)
Nervous system disorders
Transient ischaemic attack 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)
Any 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)Renal and urinary disorders
Acute kidney injury 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)
Any 2; 2 (1%) 1; 1 (1%) 3; 3 (1%)
Benign prostatic hyperplasia 1; 1 (1%) 1; 1 (1%) 2; 2 (1%)
Reproductive system and breast disorders
Priapism 1; 1 (1%) 0; 0 (0%) 1; 1 (0%)
Any 3; 2 (1%) 1; 1 (1%) 4; 3 (1%)
Acute respiratory failure 1; 1 (1%) 0; 0 (0%) 1; 1 (0%)
Diaphragmatic paralysis 1; 1 (1%) 0; 0 (0%) 1; 1 (0%)
Obliterative bronchiolitis 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)
Respiratory, thoracic and mediastinal disorders
Pleural effusion 1; 1 (1%) 0; 0 (0%) 1; 1 (0%)
Any 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)Skin and subcutaneous tissue disorders
Skin ulcer 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)
Surgical and medical procedures Any 1; 1 (1%) 3; 3 (2%) 4; 4 (1%)
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Treatment Group
Body System / Preferred Term
Somatostatin Placebo Any
Cardiac pacemaker insertion 1; 1 (1%) 0; 0 (0%) 1; 1 (0%)
Skin neoplasm excision 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)
Surgery 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)
Transurethral prostatectomy 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)
Any 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)Vascular disorders
Peripheral artery stenosis 0; 0 (0%) 1; 1 (1%) 1; 1 (0%)
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Table S3. Ocular adverse events by treatment group.
Placebo BRIM SST
Eye pain 21 41 18
Ocular hyperaemia 4 49 14
Eye pruritus 14 14 12
Anterior chamber disorder 14 8 10
Foreign body sensation 7 17 6
Dry eye 9 9 10
Lacrimation increased 7 13 4
Eye discharge 8 3 12
Vision blurred 2 7 14
Conjunctival follicles 0 16 1
Conjunctivitis 5 7 5
Blepharitis 5 6 2
Conjunctivitis allergic 1 10 2
Eyelid oedema 1 12 0
Conjunctival hyperaemia 0 9 1
Punctate keratitis 4 4 1
BRIM: brimonidine; SST: somatostatin
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Table S4. HbA1c measurements at baseline and during follow-up 
Placebo
N= 123
BRIM
N= 97
SST
N= 120
p
HbA1C at baseline (%) 7.21±0.97 7.22±1.09 7.11±0.92 n.s
HbA1C at month 6 (%) 7.23±1.08 7.19±1.14 7.14±1.07 n.s
HbA1C at month 12 (%) 7.28±1.26 7.19±1.20 7.13±0.94 n.s
HbA1C at month 18 (%) 7.22±1.27 7.01±1.13 7.25±1.17 n.s
HbA1C at month 24 (%) 7.35±1.33 7.02±1.27 7.35±1.08 n.s
Mean HbA1C (%) 7.26±1.06 7.13±1.03 7.21±0.90 n.s
Data are mean±SD
BRIM: brimonidine; SST: somatostatin
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Table S5. HbA1c measurements at baseline and during follow-up in patients with 
neurodysfunction at baseline
Placebo
N= 39
BRIM
N= 39
SST
N= 41
p
HbA1C at baseline (%) 7.19±0.98 7.25±1.12 7.12±0.91 n.s
HbA1C at month 6 (%) 7.03±1.06 7.32±1.22 7.13±1.03 n.s
HbA1C at month 12 (%) 7.09±1.04 7.30±1.33 7.17±0.98 n.s
HbA1C at month 18 (%) 7.03±0.99 6.95±0.99 7.17±1.10 n.s
HbA1C at month 24 (%) 7.16±1.10 7.05±1.05 7.37±1.19 n.s
Mean HbA1C (%) 7.09±0.94 7.15±1.05 7.21±0.94 n.s
Data are mean±SD
BRIM: brimonidine; SST: somatostatin
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Figure S1. Trial profile
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Figure S2. Evolution (upper panel) and causes (lower panel) of dropouts.
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